Novavax and Serum Institute of India to Develop and Commercialize Malaria Vaccine Candidate

GAITHERSBURG, Md., March 11 (Korea Bizwire) — Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, and Serum Institute of India (SII) today announced a commercial license agreement for the use of Novavax’ proprietary Matrix-M™ vaccine adjuvant with SII’s malaria vaccine candidate. SII licensed the R21 malaria vaccine, which [...]